Methylphenidate Hydrochloride Tillomed Laboratories

Methylphenidate Hydrochloride, the active ingredient in Methylphenidate Hydrochloride Tillomed Laboratories, is a central nervous system stimulant presented as an oral dosage form for oral use. It is indicated for the treatment of attention deficit hyperactivity disorder and narcolepsy in patients for whom these conditions have been diagnosed.

GNH USA supplies Methylphenidate Hydrochloride Tillomed Laboratories as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methylphenidate Hydrochloride is a psychostimulant used in the management of neurobehavioral disorders that affect attention and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): improves focus, reduces hyperactivity and impulsivity in children and adults. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy, helping maintain wakefulness. - Off‑label use is not listed; only the above indications are recognized for this medication.

Methylphenidate Hydrochloride may cause a range of adverse reactions, from mild to severe. Awareness of these effects supports safe monitoring.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Increased heart rate: tachycardia or palpitations. - Anxiety: heightened nervousness or restlessness.

Serious or Rare Side Effects: - Arrhythmia: abnormal heart rhythm requiring medical attention. - Hypertension: elevated blood pressure that may be severe. - Psychosis: emergence of hallucinations or delusional thoughts. - Severe allergic reaction: rash, swelling, or breathing difficulty. - Chest pain: possible sign of cardiac ischemia. - Suicidal thoughts: emergence of self‑harm ideation.

Before prescribing Methylphenidate Hydrochloride, clinicians should evaluate several safety considerations.

- Cardiovascular assessment: review patient history of heart disease, hypertension, or arrhythmias. - Psychiatric monitoring: observe for new or worsening mood disorders, psychosis, or suicidal ideation. - Growth monitoring: regularly assess height and weight in pediatric patients. - Abuse potential: use only as directed; avoid non‑medical use. - Pregnancy and lactation: discuss potential risks with the prescriber before use. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Methylphenidate Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Other sympathomimetic agents (e.g., pseudoephedrine): may cause excessive cardiovascular stimulation. - Tricyclic antidepressants: increased risk of arrhythmias and hypertension.

Moderate Interactions (Monitor Closely):\n- Selective serotonin reuptake inhibitors (SSRIs): potential for serotonin syndrome. - Antihypertensive drugs: may reduce blood‑pressure‑lowering effect. - CYP2D6 inhibitors (e.g., fluoxetine): may increase methylphenidate plasma levels. - Alcohol: can exacerbate central nervous system stimulation and cardiovascular effects.